Pittenger & Anderson Inc. Has $3.81 Million Stake in Thermo Fisher Scientific Inc. $TMO

Pittenger & Anderson Inc. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 545.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 7,742 shares of the medical research company’s stock after purchasing an additional 6,542 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Thermo Fisher Scientific were worth $3,805,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Assetmark Inc. raised its stake in shares of Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after acquiring an additional 7,023 shares during the last quarter. North Dakota State Investment Board acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $7,505,000. EdgePoint Investment Group Inc. raised its position in Thermo Fisher Scientific by 5.0% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 1,388,662 shares of the medical research company’s stock worth $673,529,000 after purchasing an additional 65,597 shares during the last quarter. Confluence Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 14.2% during the fourth quarter. Confluence Investment Management LLC now owns 95,064 shares of the medical research company’s stock worth $55,085,000 after acquiring an additional 11,841 shares during the last quarter. Finally, Focus Partners Wealth lifted its stake in shares of Thermo Fisher Scientific by 1.2% during the third quarter. Focus Partners Wealth now owns 258,747 shares of the medical research company’s stock valued at $125,514,000 after acquiring an additional 2,947 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.4%

TMO traded up $2.01 during trading on Friday, reaching $526.72. The company had a trading volume of 1,233,008 shares, compared to its average volume of 1,993,707. The business’s fifty day moving average price is $478.23 and its 200 day moving average price is $516.44. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99. The company has a market cap of $195.74 billion, a P/E ratio of 28.96, a PEG ratio of 2.33 and a beta of 0.87. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same period in the prior year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Analysts Set New Price Targets

A number of brokerages recently commented on TMO. Stifel Nicolaus lowered their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective on the stock. Finally, Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $602.14.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.